Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey

South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turkish market for hospital prescriptions.

Starting with its autoimmune disease treatment Remsima (active ingredient infliximab) in 2017, the company set up a direct sales distribution network through its locally incorporated business Celltrion Healthcare Turkiye. Last year, Remsima controlled 51% of the country's market.

The company added that its anti-cancer antibody biosimilar Herzuma (trastuzumab) last year held a commanding 71% of the market and leukemia cancer treatment Truxima (rituximab) 76%.

Beginning with Remsima SC next year, Celltrion Healthcare will use its direct sales experience to launch new products in Turkey every year like the rheumatoid arthritis medicine Yuflyma and anti-cancer drug Vegzelma.

"We will do our best to continue growth next year, when we release follow-up products on the Turkiye market, a bridgehead linking Europe, the Middle East and Asia," Celltrion Healthcare Turkiye General Manager Kang Seok-hoon said.

Write to Jeong Min Nam at peux@hankyung.com